Rationale for and efficacy of prolonged-interval treatment using liposome-encapsulated amikacin in experimental Mycobacterium avium infection.
The potential of liposome-encapsulated antibiotics for prolonging drug application intervals was investigated by using a murine model of chronic lethal Mycobacterium avium infection. Liposomal encapsulation of amikacin, but not of ciprofloxacin, resulted in high and sustained drug levels in infected tissues, exceeding the minimal inhibitory concentration for M. avium for at least 28 days. As a consequence, once-weekly and even once-monthly treatments with liposomal amikacin significantly reduced bacterial replication in infected tissues and extended the survival time of infected mice.
Leitzke
S
S
Department of Infectious Diseases, Benjamin Franklin University Clinic, Free University of Berlin, Germany. Leitzke@zedat.fu-berlin.de
Bucke
W
W
Borner
K
K
Müller
R
R
Hahn
H
H
Ehlers
S
S
D000583:Amikacin / Q000008:administration & dosage* / Q000627:therapeutic use; D000818:Animals; D000900:Anti-Bacterial Agents / Q000008:administration & dosage* / Q000627:therapeutic use; D003692:Delayed-Action Preparations; D004337:Drug Carriers; D005260:Female; D008081:Liposomes; D051379:Mice; D008810:Mice, Inbred C57BL; D009162:Mycobacterium avium / Q000187:drug effects*; D014376:Tuberculosis / Q000188:drug therapy*
D000900:Anti-Bacterial Agents; D003692:Delayed-Action Preparations; D004337:Drug Carriers; D008081:Liposomes; D000583:Amikacin